VIVUS, Inc. (NASDAQ: VVUS) has reported encouraging clinical trials of its new erectile dysfunction drug that it is developing. The company has reported that the drug was able to show results in less than half an hour thereby meeting the goals of the Phase 3 trials.
The company conducted tests on 646 patients and found that almost three quarters were ready for sexual intercourse within 30 minutes of taking the new drug Avanafil which is being tested out. This drug helps to inhibit PDE5 enzyme, which causes erectile dysfunction. The same enzyme is also attacked by well known drugs Viagra and Cialis. But the action of Avanafil is designed to be faster than its better known competitors.
The drug also has no serious side effects while some of the most common side effects are that of flushing and headaches, which are present in all erectile dysfunction drugs. VIVUS, Inc. wants to file for regulatory approval late 2010 or early 2011.
-